NCT06566651 Emotion Processing Among Patients With ALS
| NCT ID | NCT06566651 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2023-12-15 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2023-12-15 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the emotional perception in people with ALS disease compared to people with other neuromuscular disease and healthy controls. The main questions it aims to answer are: * How people with ALS judge happy and angry faces and what their "insight" into these judgements are like * How their autonomic responses differ from the other two test group Participants will asked to judge if a face presents a happy emotion or angry emotion. Researchers will compare the ALS group responses with neuromuscular diseases group and healthy control group responses to see if the ALS group judge more happy faces than angry.
Eligibility Criteria
Inclusion Criteria: * ALS patients, ambulant and hospitalized * Able to give informed consent * Diagnosed with ALS or probable ALS according to the existing revision of the El Escorial Criteria 21,22. * Patients with a peripheral neuromuscular disease, ambulant and hospitalized * Able to give informed consent * Diagnosed with a peripheral neuromuscular disease, that does not affect CNS, including but not limited to Myasthenia Gravis and polyneuropathy * Healthy controls * Able to give informed consent * Age and gender matched to ALS patients Exclusion Criteria: * All Participants * Other severe medical, neurological, or psychiatric disorders * Visual impairment to an extent that interferes with the ability to perform of the test * Severe motor or cognitive deficits, to the extent that the test-task cannot be performed * Alcohol or drug abuse to an extent the interferes with task performance * Patients with a peripheral neuromuscular disease ● Familial predisposition to ALS * Healthy controls * Familial predisposition to ALS (first degree relatives) * Medical treatment that affects the central nervous system (e.g., antidepressants)
Contact & Investigator
Mia B Heintzelmann, Cand.med
PRINCIPAL INVESTIGATOR
Department of Neurology, Aarhus University Hospital
Frequently Asked Questions
Who can join the NCT06566651 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06566651 currently recruiting?
Yes, NCT06566651 is actively recruiting participants. Contact the research team at minielse@rm.dk for enrollment information.
Where is the NCT06566651 trial being conducted?
This trial is being conducted at Aarhus, Denmark, Aalborg, Denmark.
Who is sponsoring the NCT06566651 clinical trial?
NCT06566651 is sponsored by University of Aarhus. The principal investigator is Mia B Heintzelmann, Cand.med at Department of Neurology, Aarhus University Hospital. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.